Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-03-29
2008-12-09
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S184000, C544S182000
Reexamination Certificate
active
07462614
ABSTRACT:
The present invention provides compounds of formula (I):wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
REFERENCES:
patent: 3840537 (1974-10-01), Garside et al.
patent: 3941785 (1976-03-01), Clarke et al.
patent: 4278673 (1981-07-01), Hartley et al.
patent: 4308384 (1981-12-01), Hartley et al.
patent: 4529692 (1985-07-01), Ono et al.
patent: 4838925 (1989-06-01), Tseng
patent: 6362178 (2002-03-01), Niewohner et al.
patent: 6566360 (2003-05-01), Niewohner et al.
patent: 6890922 (2005-05-01), Niewohner et al.
patent: 7122540 (2006-10-01), Niewohner et al.
patent: 2006/0189615 (2006-08-01), Niewohner et al.
patent: 10011530 (2001-09-01), None
patent: 10011530 (2001-09-01), None
patent: 1174431 (1996-10-01), None
patent: WO 2004/005291 (2004-01-01), None
Ahmed FASEB Journal 18, 5-7, 2004.
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
Cogswell J.P., et al.; Dominant-Negative Polo-Like Kinase T Induces Mitotic Catastrophe Independent of CDC25C Function; Cell Growth & Differentiation: Dec. 2000; 11; 615-628.
Glover, D.M., et al.; Polo-Like Kinases: A Team That Plays Throughout Mitosis; Genes & Development; 1998; 12; 3777-3787.
Wood, K.W., et al.; Past And Future Of The Mitotic Spindle As An Oncology Target; Current Opinion in Pharmacology; 2001; 1; 370-377.
Written Opinion Of The International Searching Authority for International Application No. PCT/US2004/009553 dated Apr. 1, 2003.
Eckerdt, F., et al.; Polo-like kinases and oncogenesis; Oncogene; 2005; 24; 267-276.
Holtrich, U., et al.; Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors; Proc. Nat. Acad. Sci. USA; 1994; 91; 1736-1740.
Yuan, J., et al.; Polo-like kinase, a novel marker for cellular proliferation; Am. J. Path.; 1997; 150; 1165-1172; abstract only.
Knecht, R., et al.; PLK (polo-like kinse), a new prognostic marker for oropharyngeal carcinomas; Int. J. Cancer; 2000; 89; 535-536.
Knecht, R., et al.; Prognistic Significance of Polo-like Kinase (PLK) Expression in Squamous Cell Carcinomas of the Head and Neck; Cancer Research; 1999; 59; 2794-2797.
MacMillan, J., et al.; Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer; Ann. Surg. Oncology; 2001; 8(9); 729-740.
Strebhardt, K., et al.; Prognostic Value of Pololike Kinase Expression in Melanomas; JAMA; 2000; 283; 479-480.
Wolf, G., et al.; Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer; Oncogene; 1997; 14; 543-549.
Takai, N., et al.; Polo-like kinase (PLK) expression in endometrial carcinoma; Cancer Letters; 2001; 169; 41-49.
Takahashi, T., et al.; Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers; Cancer Sci.; 2003; 94(2); 148-152.
Ito, Y., et al.; Polo-like kinase 1 over expression is an early event in the progression of papillary carcinoma; Br. J. Cancer; 2004; 90; 414-418.
Weichert, W., et al.; Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma; Br. J. Cancer; 2004; 90; 815-821.
Gray, P., et al.; Identification of human polo-like kianse 1 as a potential therapeutic target in pancreatic cancer; Mol. Cancer Ther.; 2004; 3; 641-646.
Whitfield, M., et al.; Common Markers of Proliferation; Nature Reviews Cancer; 2006; 6; 99-106.
Weichert, W., et al.; Polo-like kinase 1 is Overexpressed in Prostate Cancer and Linked to Higher Tumor Grades; Prostate; 2004; 60; 240-245.
Cheung Mui
King Nigel Paul
Kuntz Kevin Wayne
Mook, Jr. Robert Anthony
Pobanz Mark Andrew
Balasubram Venkataraman
Deppenbrack Bonnie L.
Smithkline Beecham Corporation
LandOfFree
Imidazotriazine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazotriazine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazotriazine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045371